Phage Therapy As a Renewed Therapeutic Approach to Mycobacterial Infections: a Comprehensive Review

Overview

Journal Infect Drug Resist

Publisher Dove Medical Press

Date 2019 Oct 2

PMID 31571947

Citations 31

Authors

Taher Azimi

Mehrdad Mosadegh

Mohammad Javad Nasiri

Sahar Sabour

Samira Karimaei

Ahmad Nasser

Affiliations

Soon will be listed here.

Abstract

Mycobacterial infections are considered to a serious challenge of medicine, and the emergence of MDR and XDR tuberculosis is a serious public health problem. Tuberculosis can cause high morbidity and mortality around the world, particularly in developing countries. The emergence of drug-resistant Mycobacterium infection following limited therapeutic technologies coupled with the serious worldwide tuberculosis epidemic has adversely affected control programs, thus necessitating the study of the role bacteriophages in the treatment of mycobacterial infection. Bacteriophages are viruses that are isolated from several ecological specimens and do not exert adverse effects on patients. Phage therapy can be considered as a significant alternative to antibiotics for treating MDR and XDR mycobacterial infections. The useful ability of bacteriophages to kill spp has been explored by numerous research studies that have attempted to investigate the phage therapy as a novel therapeutic/diagnosis approach to mycobacterial infections. However, there are restricted data about phage therapy for treating mycobacterial infections. This review presents comprehensive data about phage therapy in the treatment of mycobacterial infection, specifically tuberculosis disease.

Citing Articles

GOPhage: protein function annotation for bacteriophages by integrating the genomic context.

Guan J, Ji Y, Peng C, Zou W, Tang X, Shang J Brief Bioinform. 2025; 26(1.

PMID: 39838963 PMC: 11751364. DOI: 10.1093/bib/bbaf014.

An Exploratory Review of the Potential of Lytic Proteins and Bacteriophages for the Treatment of Tuberculosis.

Mtimka S, Pillay P, Kwezi L, Pooe O, Tsekoa T Microorganisms. 2024; 12(3).

PMID: 38543621 PMC: 10975913. DOI: 10.3390/microorganisms12030570.

Rv2617c is involved in stress response and phage infection resistance.

Moukendza Koundi L, Ekomi Moure U, Boni F, Hamdi I, Fan L, Xie J Heliyon. 2024; 10(5):e27400.

PMID: 38495141 PMC: 10943396. DOI: 10.1016/j.heliyon.2024.e27400.

Bacteriophage therapy for the treatment of Mycobacterium tuberculosis infections in humanized mice.

Yang F, Labani-Motlagh A, Bohorquez J, Moreira J, Ansari D, Patel S Commun Biol. 2024; 7(1):294.

PMID: 38461214 PMC: 10924958. DOI: 10.1038/s42003-024-06006-x.

Bacteriophage infection and killing of intracellular .

Schmalstig A, Wiggins A, Badillo D, Wetzel K, Hatfull G, Braunstein M mBio. 2023; 15(1):e0292423.

PMID: 38059609 PMC: 10790704. DOI: 10.1128/mbio.02924-23.

References

Grylak-Mielnicka A, Bidnenko V, Bardowski J, Bidnenko E . Transcription termination factor Rho: a hub linking diverse physiological processes in bacteria. Microbiology (Reading). 2016; 162(3):433-447. DOI: 10.1099/mic.0.000244. View

McClure W, Cech C . On the mechanism of rifampicin inhibition of RNA synthesis. J Biol Chem. 1978; 253(24):8949-56. View

Kamilla S, Jain V . Mycobacteriophage D29 holin C-terminal region functionally assists in holin aggregation and bacterial cell death. FEBS J. 2015; 283(1):173-90. DOI: 10.1111/febs.13565. View

Torrado E, Fraga A, Logarinho E, Martins T, Carmona J, Gama J . IFN-gamma-dependent activation of macrophages during experimental infections by Mycobacterium ulcerans is impaired by the toxin mycolactone. J Immunol. 2009; 184(2):947-55. DOI: 10.4049/jimmunol.0902717. View

Shadrin A, Sheppard C, Savalia D, Severinov K, Wigneshweraraj S . Overexpression of Escherichia coli udk mimics the absence of T7 Gp2 function and thereby abrogates successful infection by T7 phage. Microbiology (Reading). 2012; 159(Pt 2):269-274. PMC: 3709561. DOI: 10.1099/mic.0.064527-0. View

Trigo G, Martins T, Fraga A, Longatto-Filho A, Castro A, Azeredo J . Phage therapy is effective against infection by Mycobacterium ulcerans in a murine footpad model. PLoS Negl Trop Dis. 2013; 7(4):e2183. PMC: 3636042. DOI: 10.1371/journal.pntd.0002183. View

van der Paardt A, Wilffert B, Akkerman O, de Lange W, van Soolingen D, Sinha B . Evaluation of macrolides for possible use against multidrug-resistant Mycobacterium tuberculosis. Eur Respir J. 2015; 46(2):444-55. DOI: 10.1183/09031936.00147014. View

Rhoads D, Wolcott R, Kuskowski M, Wolcott B, Ward L, Sulakvelidze A . Bacteriophage therapy of venous leg ulcers in humans: results of a phase I safety trial. J Wound Care. 2009; 18(6):237-8, 240-3. DOI: 10.12968/jowc.2009.18.6.42801. View

Pradhan G, Shrivastva R, Mukhopadhyay S . Mycobacterial PknG Targets the Rab7l1 Signaling Pathway To Inhibit Phagosome-Lysosome Fusion. J Immunol. 2018; 201(5):1421-1433. DOI: 10.4049/jimmunol.1800530. View

10.

Sula L, SULOVA J, Stolcpartova M . Therapy of experimental tuberculosis in guinea pigs with mycobacterial phages DS-6A, GR-21 T, My-327. Czech Med. 1981; 4(4):209-14. View

11.

Basra S, Anany H, Brovko L, Kropinski A, Griffiths M . Isolation and characterization of a novel bacteriophage against Mycobacterium avium subspecies paratuberculosis. Arch Virol. 2014; 159(10):2659-74. DOI: 10.1007/s00705-014-2122-3. View

12.

Botella L, Vaubourgeix J, Livny J, Schnappinger D . Depleting Mycobacterium tuberculosis of the transcription termination factor Rho causes pervasive transcription and rapid death. Nat Commun. 2017; 8():14731. PMC: 5379054. DOI: 10.1038/ncomms14731. View

13.

Borysowski J, Weber-Dabrowska B, Gorski A . Bacteriophage endolysins as a novel class of antibacterial agents. Exp Biol Med (Maywood). 2006; 231(4):366-77. DOI: 10.1177/153537020623100402. View

14.

Jikia D, Chkhaidze N, Imedashvili E, Mgaloblishvili I, Tsitlanadze G, Katsarava R . The use of a novel biodegradable preparation capable of the sustained release of bacteriophages and ciprofloxacin, in the complex treatment of multidrug-resistant Staphylococcus aureus-infected local radiation injuries caused by exposure to Sr90. Clin Exp Dermatol. 2005; 30(1):23-6. DOI: 10.1111/j.1365-2230.2004.01600.x. View

15.

Sarfo F, Phillips R, Wansbrough-Jones M, Simmonds R . Recent advances: role of mycolactone in the pathogenesis and monitoring of Mycobacterium ulcerans infection/Buruli ulcer disease. Cell Microbiol. 2015; 18(1):17-29. PMC: 4705457. DOI: 10.1111/cmi.12547. View

16.

Einarsdottir T, Huygen K . Buruli ulcer. Hum Vaccin. 2011; 7(11):1198-203. DOI: 10.4161/hv.7.11.17751. View

17.

Johnson D, Chen Y . Ras family of small GTPases in immunity and inflammation. Curr Opin Pharmacol. 2012; 12(4):458-63. PMC: 3374043. DOI: 10.1016/j.coph.2012.02.003. View

18.

Lai M, Liu C, Jiang S, Soo P, Tu M, Lee J . Antimycobacterial Activities of Endolysins Derived From a Mycobacteriophage, BTCU-1. Molecules. 2015; 20(10):19277-90. PMC: 6332426. DOI: 10.3390/molecules201019277. View

19.

Mayer O, Jain P, Weisbrod T, Biro D, Ho L, Jacobs-Sera D . Fluorescent Reporter DS6A Mycobacteriophages Reveal Unique Variations in Infectibility and Phage Production in Mycobacteria. J Bacteriol. 2016; 198(23):3220-3232. PMC: 5105902. DOI: 10.1128/JB.00592-16. View

20.

Li L, Lee E, Shaw N . Expression, purification and crystallization of phosphoribosyl transferase from a mycobacteriophage. Acta Crystallogr F Struct Biol Commun. 2018; 74(Pt 3):161-165. PMC: 5947702. DOI: 10.1107/S2053230X18002480. View